Cargando…

Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers

BACKGROUND: Neurodegeneration occurs during the early stages of multiple sclerosis. It is an essential, devastating part of the pathophysiology. Tools for measuring the degree of neurodegeneration could improve diagnostics and patient characterization. OBJECTIVE: This study aimed to determine the di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novakova, Lenka, Axelsson, Markus, Malmeström, Clas, Imberg, Henrik, Elias, Olle, Zetterberg, Henrik, Nerman, Olle, Lycke, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882126/ https://www.ncbi.nlm.nih.gov/pubmed/29614113 http://dx.doi.org/10.1371/journal.pone.0194828

Ejemplares similares

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
por: Sandgren, Sofia, et al.
Publicado: (2023)

High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis
por: Singh, Avadhesh Kumar, et al.
Publicado: (2017)

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Historical HbA(1c) Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88
por: Lind, Marcus, et al.
Publicado: (2021)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Inflammation-related plasma and CSF biomarkers for multiple sclerosis
por: Huang, Jesse, et al.
Publicado: (2020)

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
por: Jernås, Margareta, et al.
Publicado: (2013)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Neuronal antibodies in adult patients with new‐onset seizures: A prospective study
por: Zelano, Johan, et al.
Publicado: (2019)

SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder
por: Johnsson, Magnus, et al.
Publicado: (2022)

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
por: Wasling, Pontus, et al.
Publicado: (2019)

A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland
por: Eliasdottir, Olöf, et al.
Publicado: (2017)

A Sensitive Method for Detecting Peptide-specific CD4(+) T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis
por: Sharma, Sapna, et al.
Publicado: (2017)

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
por: Toombs, Jamie, et al.
Publicado: (2020)

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs
por: Tedeholm, H, et al.
Publicado: (2013)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Weighted analysis of general microarray experiments
por: Sjögren, Anders, et al.
Publicado: (2007)

Statistical evaluation of methods for identification of differentially abundant genes in comparative metagenomics
por: Jonsson, Viktor, et al.
Publicado: (2016)

Tau as a fluid biomarker of concussion and neurodegeneration
por: Hossain, Iftakher, et al.
Publicado: (2022)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis
por: Jons, Daniel, et al.
Publicado: (2022)

Sensitive and robust gene expression changes in fish exposed to estrogen – a microarray approach
por: Gunnarsson, Lina, et al.
Publicado: (2007)

A multicentre validation study of the diagnostic value of plasma neurofilament light
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Neurofilament light in blood – What more is needed for clinical implementation in multiple sclerosis?
por: Zetterberg, Henrik
Publicado: (2020)

Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population
por: Gleerup, Helena Sophia, et al.
Publicado: (2021)

Fine Mapping of Gene Regions Regulating Neurodegeneration
por: Swanberg, Maria, et al.
Publicado: (2009)

Network diffusion model predicts neurodegeneration in limb-onset Amyotrophic Lateral Sclerosis
por: Bhattarai, Anjan, et al.
Publicado: (2022)

Plasma Markers of Neurodegeneration Are Raised in Friedreich’s Ataxia
por: Zeitlberger, Anna M., et al.
Publicado: (2018)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders
por: Eide, Per Kristian, et al.
Publicado: (2023)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

A novel method for cross-species gene expression analysis
por: Kristiansson, Erik, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kftt8vlpquhv7b7juvujngcdjk